NCT06363435 AI-based Measurements of Tumour Burden in PSMA PET-CT
| NCT ID | NCT06363435 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Elin Tragardh |
| Condition | Prostate Cancer |
| Study Type | OBSERVATIONAL |
| Enrollment | 1,500 participants |
| Start Date | 2024-03-29 |
| Primary Completion | 2031-03 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 1,500 participants in total. It began in 2024-03-29 with a primary completion date of 2031-03.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The primary aim of the present study is to evaluate how automatically calculated (by an AI-based method) tumour burden, measured as tumour volume (TV) and as tumour uptake (TU: TV x SUVmean) in the prostate/prostate bed, pelvic lymph nodes, distant lymph nodes, bone and as the total tumour burden predicts overall survival (OS) in patients with prostate cancer (newly diagnosed and patients with biochemical recurrence).
Eligibility Criteria
Inclusion Criteria: * Patients referred to a clinically indicated 18F-PSMA-1007 PET-CT scan at Skåne University Hospital, Lund or Malmö, Sweden Exclusion Criteria: * Patients under 20 years old
Contact & Investigator
Frequently Asked Questions
Who can join the NCT06363435 clinical trial?
This trial is open to male participants only, aged 20 Years or older, up to 120 Years, studying Prostate Cancer. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT06363435 currently recruiting?
Yes, NCT06363435 is actively recruiting participants. Contact the research team at elin.tragardh@skane.se for enrollment information.
Where is the NCT06363435 trial being conducted?
This trial is being conducted at Lund, Sweden, Malmö, Sweden.
Who is sponsoring the NCT06363435 clinical trial?
NCT06363435 is sponsored by Elin Tragardh. The trial plans to enroll 1,500 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.